Physician profile
Constant Ks Chan
NPI 1730195645
$23,818.99
in general payments reported to CMS, 2019-2025
62 companies · $6,116 in 2025
The $6,116 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,087 · 2020: $1,463 · 2021: $1,662 · 2022: $1,844 · 2023: $5,641 · 2024: $6,007 · 2025: $6,116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18K · Education: $88.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17,675.09 |
| Education | $88.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,026.15 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Abbvie INC. | $2,014.98 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Madrigal Pharmaceuticals | $1,775.76 | 2024-2025 | Rezdiffra, Resmetirom |
| Amgen INC. | $1,581.15 | 2019-2025 | Repatha, Otezla, Evenity |
| Janssen Pharmaceuticals, INC | $1,240.41 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $1,155.04 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,128.13 | 2019-2025 | Jardiance |
| Pfizer INC. | $975.65 | 2020-2025 | |
| Glaxosmithkline, LLC. | $962.07 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $956.41 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Merck Sharp & Dohme LLC | $798.28 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $790.96 | 2021-2025 | Xifaxan, Relistor |
| Sanofi-Aventis U.S. LLC | $705.45 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $655.76 | 2021-2025 | |
| Esperion Therapeutics, INC. | $643.04 | 2023-2025 | Nexletol, Nexlizet |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $509.26 | 2023-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $477.81 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $461.53 | 2023-2025 | Rexulti |
| Genzyme Corporation | $425.62 | 2023-2025 | |
| Verona Pharma, INC. | $384.38 | 2025 | Ohtuvayre |
| Biohaven Pharmaceutical Holding Company LTD. | $358.58 | 2022 | |
| Lundbeck LLC | $349.93 | 2023-2025 | Vyepti |
| Dexcom, INC. | $290.04 | 2022-2025 | Dexcom G6 Transmitter |
| Ardelyx, INC. | $285.10 | 2024-2025 | Ibsrela |
| Shield Therapeutics INC | $276.69 | 2023-2025 | Accrufer |
| Lexicon Pharmaceuticals, INC. | $271.52 | 2023-2024 | Inpefa |
| Paratek Pharmaceuticals, INC. | $206.57 | 2024-2025 | Nuzyra |
| Regeneron Healthcare Solutions, INC. | $189.59 | 2023-2025 | Dupixent, Evkeeza |
| Amarin Pharma, INC. | $151.44 | 2020-2023 | |
| Medtronic, INC. | $137.13 | 2022-2024 | Minimed 780g |
| Smith+Nephew, INC. | $129.90 | 2023-2025 | Collagenase Santyl, Regranex |
| Sumitomo Pharma America, INC. | $120.49 | 2024-2025 | Gemtesa |
| Biohaven Pharmaceuticals, INC. | $112.98 | 2021 | |
| Aimmune Therapeutics, INC. | $109.58 | 2024-2025 | Zenpep, Vowst |
| Antares Pharma, INC. | $95.89 | 2023-2024 | Xyosted, Nocdurna, Tlando |
| Janssen Biotech, INC. | $83.48 | 2024-2025 | Tremfya, Xarelto |
| Abbott Laboratories | $73.59 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Ironwood Pharmaceuticals, INC | $73.10 | 2023-2024 | Linzess |
| Arbor Pharmaceuticals, INC. | $72.16 | 2019-2020 | |
| Corium, LLC | $70.46 | 2023 | Adlarity |
| Halozyme INC | $68.14 | 2023 | |
| Allergan, INC. | $56.50 | 2020 | |
| Phathom Pharmaceuticals, INC. | $56.38 | 2025 | Voquezna |
| Organon LLC | $55.29 | 2023 | Nexplanon |
| Takeda Pharmaceuticals U.S.A., INC. | $38.80 | 2023 | Trintellix |
| Idorsia Pharmaceuticals US INC | $36.91 | 2023-2025 | Quviviq, Quviviq |
| Teva Pharmaceuticals USA, INC. | $34.91 | 2019-2025 | Austedo Xr |
| Redhill Biopharma INC. | $34.28 | 2024 | Talicia |
| Vertex Pharmaceuticals Incorporated | $34.18 | 2025 | |
| Mannkind Corporation | $30.42 | 2023 | Afrezza |
| E.R. Squibb & Sons, L.L.C. | $28.69 | 2024-2025 | Eliquis |
| Gilead Sciences, INC. | $25.00 | 2023 | |
| Exeltis, USA INC. | $23.00 | 2023 | Slynd |
| Nestle Healthcare Nutrition INC. | $22.96 | 2023 | |
| Ionis Pharmaceuticals, INC. | $21.57 | 2025 | Tryngolza |
| Amryt Pharma Holdings LTD | $20.19 | 2023 | Juxtapid |
| Optinose US, INC. | $19.10 | 2019 | |
| Theracosbio, LLC | $18.49 | 2024 | Brenzavvy |
| Horizon Therapeutics Plc | $18.47 | 2023 | Tepezza |
| Opko Pharmaceuticals, LLC | $17.52 | 2022 | |
| Seqirus USA INC | $17.25 | 2025 | Fluad, Flucelvax |
| Corcept Therapeutics | $14.88 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Constant Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.